Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2019-07-03 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金临时性补充流动资金归还的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 瑞康医药集团股份有限公司 regarding the temporary use and subsequent full repayment of idle raised funds to supplement working capital. It details the board and supervisory committee approvals, the amount used, the usage period, and the repayment date. The document is short (800 characters) and serves as a formal notification of a capital usage and repayment event rather than a detailed financial report or earnings release. It does not contain financial statements or detailed analysis but is an update on capital structure and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-07-03 Chinese
关于2018年第一期员工持股计划完成购买的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a company's employee stock ownership plan purchase. It details the number of shares bought, the transaction amount, and the lock-up period. The document is relatively short (1086 characters) and focuses on reporting the progress of a capital-related activity (employee stock purchase). It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is not an Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or a voting result announcement. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activity through employee stock ownership plan purchases.
2019-06-27 Chinese
关于深圳证券交易所2018年年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2018 annual report. It contains extensive financial data, explanations of revenue growth, profit changes, cash flow analysis, credit policies, bad debt provisions, asset securitization, and management of subsidiaries. The document references the 2018 annual report multiple times and includes auditor opinions on the financial data and accounting treatments. The length (15,000 characters) and depth of financial and operational detail indicate this is not a brief announcement or a certification but a substantive financial report. The content aligns with a comprehensive annual report or a detailed reply to regulatory inquiries about the annual report. Given the focus on the 2018 annual report and the nature of the content, the filing type is Annual Report (10-K). FY 2018
2019-06-21 Chinese
北京天圆全会计事务所（特殊普通合伙）关于公司2018年年报问询函的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an accounting firm (Beijing Tianyuanquan Certified Public Accountants LLP) to an inquiry letter from the Shenzhen Stock Exchange regarding the 2018 annual report of Ruikang Pharmaceutical Group Co., Ltd. It contains extensive audit opinions, explanations of financial figures such as revenue, net profit, cash flow, accounts receivable, bad debt provisions, inventory valuation, and goodwill impairment. The document includes detailed financial analysis, accounting policies, and audit conclusions related to the company's 2018 fiscal year. The presence of audit opinions and detailed financial data related to the annual report indicates this is an Audit Report / Information document rather than the full Annual Report itself. It is not a brief announcement or a certification letter but a comprehensive audit response with substantive financial content. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2018
2019-06-21 Chinese
2017年面向合格投资者公开发行公司债券（第一期）、2018年面向合格投资者公开发行公司债券（第一期）受托管理事务报告（2018年度）
Audit Report / Information Classification · 95% confidence The document is titled as a "2018年度受托管理事务报告" (2018 Annual Trustee Management Affairs Report) related to company bonds issued by 瑞康医药集团股份有限公司. It contains detailed information about the issuance, terms, usage of proceeds, financial status of the issuer in 2018, bond repayment status, bondholder meetings, credit rating updates, and trustee management activities. The document includes comprehensive financial data such as consolidated balance sheets, profit and loss statements, and cash flow statements for 2018, as well as operational and management details related to the bonds. It is not a full annual report (10-K) but a specialized report focused on bond trustee management and related financial and operational disclosures. It is not a simple announcement or certification but a substantive report with financial data and analysis. Therefore, the document fits best into the category of Audit Report / Information (AR), which includes standalone audit reports and related financial disclosures excluding full annual reports. FY 2018
2019-06-21 Chinese
2018年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2018 by 瑞康医药集团股份有限公司. It details the dividend distribution plan approved at the 2018 Annual General Meeting held on May 21, 2019, including the dividend amount per share, the record date, ex-dividend date, and the method of dividend payment. The document is an announcement of the implementation of the dividend distribution plan rather than the dividend report itself. It does not contain comprehensive financial statements or detailed financial performance data. The document length is 2484 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders.
2019-06-20 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.